Evidence map›Paper›PMID 38038946›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Engineering Selective TIMPs Using a Counter-Selective Screening Strategy.

Hannaneh Ahmadighadykolaei, Evette S Radisky, Maryam Raeeszadeh-Sarmazdeh

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Hannaneh AhmadighadykolaeiDepartment of Chemical and Materials Engineering, University of Nevada, Reno, NV, USA.
Evette S RadiskyMayo Clinic, Cancer Biology, Jacksonville, FL, USA.
Maryam Raeeszadeh-SarmazdehDepartment of Chemical and Materials Engineering, University of Nevada, Reno, NV, USA. maryamr@unr.edu.
University of Nevada, Reno · USMayo Clinic in Florida · US

Funding

Virtual Reality and Augmented Reality CoreP20GM103650 · NIGMS · UNIVERSITY OF NEVADA RENO · PI WEBSTER, MICHAEL A · 2012 to 2022
$20.9M
Proteolysis in the Pathogenesis of ARDSR01HL157424 · NHLBI · NATIONAL JEWISH HEALTH · PI DOWNEY, GREGORY PAUL, RADISKY, DEREK C · 2022 to 2025
$2.8M
Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapyR01CA258274 · NCI · MAYO CLINIC JACKSONVILLE · PI RADISKY, EVETTE S · 2021 to 2025
$1.6M
Engineering selective inhibition of metalloproteinases by tissue inhibitors of metalloproteinases (R01 GM132100 RESUB - *TIMPs)R01GM132100 · NIGMS · MAYO CLINIC JACKSONVILLE · PI RADISKY, EVETTE S · 2020 to 2023
$1.3M
Selective targeting of matrix metalloproteinases for developing preterm labor therapeuticsR21HD109743 · NICHD · UNIVERSITY OF NEVADA RENO · PI RAEESZADEH SARMAZDEH, MARYAM · 2022 to 2024
$399k
Directed evolution of tissue inhibitor of metalloproteinase 3 (TIMP-3) to develop novel Alzheimer’s disease (AD) therapeuticsR03AG070511 · NIA · UNIVERSITY OF NEVADA RENO · PI RAEESZADEH SARMAZDEH, MARYAM · 2022 to 2022
$300k
NCI NIH HHS R01 CA258274NHLBI NIH HHS R01 HL157424NIA NIH HHS R03 AG070511NICHD NIH HHS R21 HD109743NIGMS NIH HHS P20 GM103650NIGMS NIH HHS R01 GM132100
6 · The paper itself

Abstract

The yeast surface display platform provides a powerful approach for screening protein diversity libraries to identify binders with an enhanced affinity toward a binding partner. Here, we describe an adaptation of the approach to identify binders with enhanced specificity toward one among multiple closely related binding partners. Specifically, we describe methods for engineering selective matrix metalloproteinase (MMP) inhibitors via yeast surface display of a tissue inhibitor of metalloproteinase (TIMP) diversity library coupled with a counter-selective screening strategy. This protocol may also be employed for developing selective protein binders or inhibitors toward other targets.

Indexed as

Matrix Metalloproteinase InhibitorsSaccharomyces cerevisiaeMetalloproteasesProteinsTissue Inhibitor of Metalloproteinase-1Matrix Metalloproteinase InhibitorsMetalloproteasesProteinsTissue Inhibitor of Metalloproteinase-1Directed evolutionEnzyme inhibitorsExtracellular matrixFluorescence-activated cell sortingMatrix metalloproteinaseRational design of proteinsTissue inhibitor of metalloproteinasesYeast surface display

Identifiers

PMID38038946
PMCPMC11235094
OpenAlexW4389244924

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.